
In a U-turn on its previous guidance NICE is now recommending that the £330,000 rare disease drug Soliris should be …

The UK healthcare system is at risk of failing to adopt new, personalised medicines and must be willing to pay …

NICE is to be responsible next year for assessing high cost drugs for people with rare medical conditions as part …
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

